In an ongoing confirmatory trial, investigators rarely re-challenge PD-1 refractory patients with another PD-1 inhibitor alone. This real-world clinical consensus, viewing the practice as futile, provides strong practical evidence that the nivolumab in the combination isn't the sole driver of efficacy, supporting RP1's significant contribution.
The RP1 trial preempted regulatory concerns about its single-arm design by employing an unusually rigorous definition of PD-1 immunotherapy failure. This standard, which exceeded consensus guidelines, included mandatory scan confirmations and blinded independent reviews, ensuring the study population was truly refractory and bolstering the data's credibility.
While both RP1+nivolumab and TIL therapy treat post-PD-1 melanoma, they serve different segments. RP1 is positioned for broad, universal appeal due to its simpler administration. This contrasts sharply with the complex, multi-step, high-toxicity process for TILs (harvesting, manufacturing, chemotherapy), which fits a more specific and robust patient profile.
To maximize the oncolytic virus RP1's efficacy, clinicians must inject a diversity of lesions, including visceral ones in the liver and lung, not just easily accessible surface tumors. This necessitates a close operational partnership with interventional radiology, making it a critical logistical requirement for any institution planning to adopt the therapy.